

Company Overview

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a leader in precision medicine with immuno-targeted products designed to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making, targeted treatment and, ultimately, patient care. Applying our Manocept™ technology, Navidea seeks to develop next-generation targeted diagnostics and therapies for cancer, autoimmune conditions, and other inflammatory diseases. The company, founded in 1983, maintains headquarters in Dublin, Ohio.

Navidea Biopharmaceuticals Reports Third Quarter 2021 Financial Results

Nov 10 2021, 4:01 PM EST

Navidea Biopharmaceuticals to Host Third Quarter 2021 Earnings Conference Call and Business Update

Nov 3 2021, 4:01 PM EDT

Navidea Biopharmaceuticals Announces Resignation of Jed A. Latkin

Oct 26 2021, 5:22 PM EDT

Stock Overview

Symbol	NAVB
Exchange	NYSE American
Market Cap	
Last Price	\$
52-Week	\$ - \$

Investor Relations

Jeffrey Smith
Vice President, Operations
T: 614-822-2365
jsmith@navidea.com

Management Team

Michael Rosol, Ph.D.

Chief Medical Officer

Michel Mikhail, Ph.D.

Chief Regulatory Officer

William Regan

Chief Strategy Officer and Chief Compliance Officer

Navidea Biopharmaceuticals, Inc.

4995 Bradenton Avenue
Suite 240
Dublin, OH 43017

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.